Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4418
- Book/Share 8.5941
- PB 5.264
- Debt/Equity 2.9211
- CurrentRatio 1.2068
- ROIC 0.1328
- MktCap 91798156294.0
- FreeCF/Share 7.1636
- PFCF 6.297
- PE 18.1776
- Debt/Assets 0.5379
- DivYield 0.0545
- ROE 0.2957
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Buy These 2 Beaten Down Stocks Now Before They Rally
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headwinds, but offer attractive entry points for patient investors seeking multi-year recovery and income. AAT is undervalued due to office exposure and California concentration, but has solid financials, a safe dividend, and multifamily growth potential.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42% and forward dividend income reaching $2,195.04. Added to positions in Bristol-Myers Squibb, Pfizer, and BP, focusing on undervalued stocks with strong dividend yields and growth potential.
Read More
First-Quarter GDP Halfway to Recession: Move to These Safe High-Yield Dividend Stocks Now
Published: May 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
The first report for U.S. gross domestic product (GDP) came in at −0.3% as the economy contracted for the first time in three years.
Read More
This High-Yield Pharma Stock Looks Like an Incredible Bargain
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of economic conditions.
Read More
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.
Read More
Bristol-Myers: Undervalued, Delivering Increased 2025 Guidance
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
Despite recent underperformance, Bristol-Myers' strong cash position, robust pipeline, and strategic acquisitions position it for future growth, making it an undervalued opportunity. BMY's growth portfolio is thriving, with significant YoY increases in key drugs, offsetting declines in its legacy products. BMY's consistent dividend growth and strong profitability make it an attractive income investment, especially as the Fed reduces rates.
Read More
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
Read More
Jobless Claims Increased in Line With Expectations
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Ahead of the opening bell this Thursday morning, Initial Jobless Claims came in at 222K for last week, slightly above estimates but certainly within range that demonstrates a continued healthy labor market. The previous week's print of 216K was ratcheted up just slightly on revision.
Read More
Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call Transcript
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (NYSE:BMY ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Chuck Triano - SVP and Head of IR Chris Boerner - Board Chair and CEO David Elkins - CFO Adam Lenkowsky - CCO Samit Hirawat - CMO and Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Geoff Meacham - Citi Evan Seigerman - BMO Capital Terence Flynn - Morgan Stanley Trung Huynh - UBS Courtney Breen - Bernstein Tim Anderson - Bank of America David Risinger - Leerink Partners …
Read More
Bristol-Myers Squibb Is A Good Pick
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb Company is undervalued, trading 30% below its intrinsic value, with a low price-to-free-cash-flow ratio indicating a strong buying opportunity. In the first quarter, Bristol-Myers Squibb did beat expectations for revenue and earnings per share, but had to report declining sales. Management expects a revenue decline in 2025 due to legacy portfolio drops, but growth portfolio and promising pipeline offer long-term potential.
Read More
Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to loss of $4.40 per share a year ago.
Read More
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
Published: April 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
Read More
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
Read More
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Hedge Funds Are Dumping Tech Stocks: Grab These 4 Safety Net High-Yield Dividend Giants Now
Published: April 04, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Hedge funds are rapidly reducing their exposure to global information technology stocks, with the latest selloff marking the fastest decline in six months.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1
Published: March 28, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100